AbbVie Files for FDA Approval of Cancer Therapy

The pharmaceutical company submitted a biologics license application for its new bispecific antibody, etentamig.

Updated on Oct. 28, 2026 in Cancer

Isometric editorial illustration of a metallic laboratory centrifuge rotor, representing the precision of new pharmaceutical research and regulatory approval processes. — AbbVie has submitted a biologics license application to the FDA for etentamig, a new bispecific antibody designed for the treatment of cancer. AI Illustration. Upload story photo >

AbbVie submitted a biologics license application for etentamig, an investigational intravenous bispecific antibody for cancer treatment. The filing follows positive results from a Phase 3 study comparing the therapy to current standard treatments.

Why it matters

The FDA review will determine if the therapy is safe and effective enough for widespread clinical use in the United States. If approved, etentamig could provide a new option for patients who do not respond adequately to existing standards of care.

The Phase 3 CERVINO trial involving 393 patients showed etentamig patients had a 74.0% overall response rate compared to 45.7% for standard therapy. Patients receiving the investigational drug experienced a 60% lower hazard of progression or death.

The players

AbbVie

A research-based biopharmaceutical company that develops and manufactures medicines for complex health conditions.

The details

The CERVINO trial utilized 1:1 randomization to compare etentamig to standard therapy, with participants receiving the drug monthly following a single step-up dose. The study maintained a median duration of follow-up of 11.4 months to evaluate patient outcomes.

October 27, 2026: AbbVie filed the biologics license application for FDA review.

Health Landscape

This filing initiates the formal regulatory review cycle required for the approval of new biologic therapies within the FDA's biologics license application review process. It highlights the continued clinical development of bispecific antibodies as a new therapeutic class.

The outcome of this FDA review will determine if patients eventually gain access to etentamig as a new treatment option. Until then, patients remain reliant on existing standard therapies currently approved for their specific conditions.

The takeaway

The submission represents a significant milestone for AbbVie's oncology portfolio as it advances through regulatory evaluation. Patients and providers should continue to monitor FDA announcements for future updates regarding potential market authorization.